Growth factors and protein kinase C inhibitors as novel therapies for the medical management diabetic retinopathy.
Diabetic retinopathy is a leading cause of acquired visual loss. Current treatment modalities are not effective in all cases and may have side effects. Investigation of the biochemical basis of diabetic retinopathy suggests that future treatments may reverse or halt the progression of diabetic retinopathy, or actually prevent the development of diabetic retinopathy. Pharmacological manipulation of protein kinase C and various growth factors may form the basis of future treatments for diabetic retinopathy.
Aiello
L P
LP
Beetham Eye Institute, Joslin Diabetes Center, Boston, MA 02215, USA. LPAiello@joslin.harvard.edu
Cahill
M T
MT
Cavallerano
J D
JD
D042501:Angiogenic Proteins / Q000037:antagonists & inhibitors; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006131:Growth Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D011493:Protein Kinase C / Q000037:antagonists & inhibitors*; D012171:Retinal Vessels / Q000187:drug effects
D042501:Angiogenic Proteins; D004791:Enzyme Inhibitors; D006131:Growth Inhibitors; D011493:Protein Kinase C